Practical implication
Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.
A new reporting requirement for the extension of marketing authorisation has been established by the EMA, effective from July 24, 2026 to August 20, 2026.
What changed: A new reporting requirement has been introduced related to the extension of marketing authorisation for pharmaceutical products during the period from July 24, 2026 to August 20, 2026.
Why it matters: This change necessitates updated regulatory oversight and compliance workflows for pharmaceutical products seeking to extend their marketing authorisation.
Practical implication: Regulatory Intelligence Leads must incorporate the new reporting requirements and deadlines into their monitoring activities for affected products.
View original source
- Source: EMA - What's new RSS
- Published at source: 2026-08-26T00:00:00.000Z
- Discovered by monitor: 2026-08-26T22:30:49.183Z
Published from the regulator source ingestion pipeline after PV impact triage.
